MedTrace Logo

Cosopt Versus Xalatan

NCT00273429 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2007-01-09

No results posted yet for this study

Summary

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Conditions

Interventions

DRUG

timolol maleate 0.5%

DRUG

dorzolamide/timolol maleate fixed combination

DRUG

latanoprost 0.005%

DRUG

placebo

Sponsors & Collaborators

  • Pharmaceutical Research Network

    lead OTHER

Principal Investigators

  • William C. Stewart, MD · Pharmaceutical Research Network, LLC

  • Jay Mulaney, MD · Central Florida Eye Associates

  • Sriram Sonty, MD, FACS · Midwest Eye Center SC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00273429 on ClinicalTrials.gov